Sindelar W F, Maher M M, Herlyn D, Sears H F, Steplewski Z, Koprowski H
Hybridoma. 1986 Jul;5 Suppl 1:S125-32.
Monoclonal antibody 17-1A was administered to 25 patients with advanced unresectable carcinoma of the pancreas. Ten patients received 17-1A alone in 400 mg doses delivered intravenously, while 15 patients received 400 mg 17-1A absorbed on to autologous peripheral blood mononuclear cells collected by leukapheresis (usual yield greater than 10(9) cells). No toxicity was observed. Twenty-three patients developed circulating anti-murine immunoglobulin within three weeks of treatment, and 11 patients developed circulating anti-idiotypic immunoglobulin. Four out of 19 clinically evaluable patients (21%) showed objective regressions of tumor. Response did not correlate with the presence or absence of anti-idiotypic antibody and did not correlate with the method of treatment with 17-1A alone or 17-1A and mononuclear cells, at the time of current analysis.
对25例无法切除的晚期胰腺癌患者施用单克隆抗体17-1A。10例患者单独静脉注射400mg剂量的17-1A，而15例患者接受吸附于通过白细胞分离术采集的自体外周血单个核细胞（通常产量大于10⁹个细胞）上的400mg 17-1A。未观察到毒性。23例患者在治疗后三周内出现循环抗鼠免疫球蛋白，11例患者出现循环抗独特型免疫球蛋白。19例可进行临床评估的患者中有4例（21%）显示肿瘤客观消退。在当前分析时，反应与抗独特型抗体的存在与否无关，也与单独使用17-1A或17-1A与单个核细胞的治疗方法无关。
